Anixa Biosciences, Inc. reported earnings results for the full year ended October 31, 2022. For the full year, the company reported net loss was USD 13.6 million compared to USD 12.95 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.45 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.21 USD | -7.14% |
|
-12.30% | -43.04% |
24/06 | Anixa Biosciences Says Sixth Patient Treated in Phase 1 Ovarian Cancer Study | MT |
24/06 | Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.04% | 7.07Cr | |
+19.41% | 4.55TCr | |
-8.62% | 3.85TCr | |
+38.65% | 3.81TCr | |
+26.95% | 3.07TCr | |
-13.50% | 2.6TCr | |
+10.74% | 2.59TCr | |
+44.87% | 1.41TCr | |
+34.36% | 1.27TCr | |
-7.14% | 1.13TCr |
- Stock Market
- Equities
- ANIX Stock
- News Anixa Biosciences, Inc.
- Anixa Biosciences, Inc. Reports Earnings Results for the Full Year Ended October 31, 2022